Disease progression in some cancers may be due to low blood levels of targeted therapies.
Tuma
Rabiya S
RS
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics; D001549:Benzamides; D001682:Biological Availability; D000069439:Dasatinib; D018450:Disease Progression; D004334:Drug Administration Schedule; D004347:Drug Interactions; D019008:Drug Resistance, Neoplasm; D046152:Gastrointestinal Stromal Tumors / Q000097:blood / Q000188:drug therapy; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy; D009369:Neoplasms / Q000097:blood* / Q000188:drug therapy*; D010349:Patient Compliance; D010879:Piperazines / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000097:blood; D011743:Pyrimidines / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics; D013844:Thiazoles / Q000008:administration & dosage / Q000097:blood
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D000069439:Dasatinib